Top Page
Pro Medicus Limited
(Sydney:PME)
Pro Medicus Limited (PME) vs. iShares MSCI Australia ETF (EWA)
Pro Medicus Limited Business Overview & Revenue Model
Pro Medicus Limited Earnings Call Summary
Pro Medicus Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 212.98M | 212.91M | 161.43M | 124.90M | 93.46M | 67.88M |
| Gross Profit | 169.16M | 212.60M | 122.24M | 92.36M | 92.94M | 46.66M |
| EBITDA | 170.62M | 164.85M | 120.69M | 91.69M | 69.64M | 49.53M |
| Net Income | 115.22M | 115.22M | 82.79M | 60.65M | 44.44M | 30.85M |
Balance Sheet | ||||||
| Total Assets | 338.70M | 338.70M | 257.43M | 202.13M | 157.05M | 125.57M |
| Cash, Cash Equivalents and Short-Term Investments | 209.19M | 209.19M | 154.89M | 121.50M | 90.55M | 61.82M |
| Total Debt | 2.25M | 2.25M | 2.07M | 1.85M | 2.28M | 2.62M |
| Total Liabilities | 81.74M | 81.74M | 69.70M | 63.36M | 55.32M | 43.89M |
| Stockholders Equity | 256.96M | 256.96M | 187.73M | 138.78M | 101.73M | 81.68M |
Cash Flow | ||||||
| Free Cash Flow | 118.43M | 103.95M | 80.08M | 58.33M | 53.20M | 31.33M |
| Operating Cash Flow | 118.87M | 111.33M | 86.78M | 64.77M | 62.23M | 39.02M |
| Investing Cash Flow | -14.12M | -6.58M | -78.07M | -9.79M | -17.56M | -27.40M |
| Financing Cash Flow | -57.62M | -57.62M | -39.84M | -27.53M | -23.31M | -14.05M |
Pro Medicus Limited Technical Analysis
Pro Medicus Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $29.43B | 255.39 | 50.70% | 0.19% | 31.88% | 39.10% | |
| ― | AU$127.58M | 79.17 | 1.89% | ― | 10.06% | ― | |
| ― | AU$102.29M | ― | -8647.54% | ― | 25.98% | 21.43% | |
| ― | AU$23.07M | 140.00 | -17.05% | ― | 28.91% | -1050.00% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $69.32M | ― | -12.35% | ― | 15.99% | 22.05% | |
| ― | AU$17.71M | 110.00 | -240.60% | ― | -48.41% | -7200.00% |
Pro Medicus Limited Corporate Events
Pro Medicus Limited has announced its Annual General Meeting (AGM) scheduled for November 24, 2025, which will be conducted as a hybrid meeting. Shareholders can participate in person or online, with provisions made for voting and asking questions through a dedicated portal. This meeting is crucial for stakeholders to engage with the company’s board and discuss resolutions, reflecting Pro Medicus’s commitment to transparency and shareholder engagement.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$317.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has secured a 5-year, A$10 million contract to implement its Visage 7 Enterprise Imaging Platform at University Hospital Heidelberg and the German Cancer Research Institute, among other associated hospitals. This deal expands Pro Medicus’s presence in the European market, replacing and consolidating existing legacy systems to enhance diagnostic and research capabilities, thereby supporting cutting-edge medical research and patient care.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$333.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited announced that it is not affected by the recently announced US tariffs on pharmaceuticals, as the company does not engage in the production or sale of pharmaceutical products. This clarification ensures that Pro Medicus’s operations remain unaffected by these tariffs, maintaining its focus on providing cutting-edge medical imaging solutions without any direct implications from the pharmaceutical industry tariffs.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$333.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited announced a change in the director’s interest, with Dr. Sam Aaron Hupert acquiring 50,000 ordinary shares through an off-market transfer. This transfer, valued at $299 per share, increases Dr. Hupert’s total holdings to 24,187,660 shares, reflecting a strategic move in consolidating his stake in the company.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited announced that its U.S. subsidiary, Visage Imaging, Inc., has received an Authority to Operate (ATO) from the U.S. Department of Veterans’ Affairs for its Visage 7 | CloudPACS platform. This milestone allows the transition of their current on-premise system to the Veterans Affairs Enterprise Cloud, marking a significant step in their collaboration with the Veterans’ Health Administration. The achievement is expected to serve as a reference for other Veterans’ Integrated Service Networks considering cloud migration, potentially enhancing Pro Medicus’s positioning in the federal healthcare sector.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$338.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited’s recent earnings call painted a picture of robust financial health, underscored by record revenue and profit growth. The company celebrated significant contract wins and advancements in cloud and AI technology, although it acknowledged challenges in expanding its market presence outside North America and navigating a competitive landscape.
Pro Medicus Limited announced the cessation of 47,930 performance rights due to unmet conditions, as of August 25, 2025. This development may affect the company’s capital structure and could have implications for stakeholders regarding the company’s performance metrics and future financial planning.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$361.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has announced the quotation of 47,930 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of August 25, 2025. This move reflects the company’s ongoing efforts to enhance its market presence and provide value to its stakeholders by expanding its financial instruments available for trading.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$361.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited is a leading healthcare informatics company specializing in medical imaging software and services for hospitals and healthcare groups across Australia, Europe, and North America. The company has reported a strong financial performance for the year ended June 30, 2025, with a 31.9% increase in revenue to $213 million and a 39.2% rise in profit after tax to $115.2 million. Key highlights include the acquisition of seven new long-term contracts in North America, a robust pipeline of opportunities, and continued expansion in cloud-based solutions. Pro Medicus remains debt-free with strong cash reserves, supporting a 37.5% increase in declared dividends to 55 cents per share. The company is well-positioned for future growth, driven by its innovative Visage 7 platform and strategic focus on cloud deployment and AI integration. Looking ahead, Pro Medicus aims to capitalize on the growing demand for cloud-based healthcare solutions and maintain its leadership in the medical imaging sector.
Pro Medicus Limited has announced a dividend distribution of AUD 0.30 per share for its ordinary fully paid securities, with an ex-date of September 3, 2025, and a payment date of September 25, 2025. This announcement reflects the company’s stable financial performance and commitment to returning value to its shareholders, potentially strengthening its position in the healthcare technology market.
The most recent analyst rating on (AU:PME) stock is a Hold with a A$130.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has released its corporate governance statement for the financial year ending June 30, 2025, which is available on its website. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, demonstrating its commitment to transparency and accountability. This announcement is significant as it highlights Pro Medicus’s dedication to maintaining high governance standards, which is crucial for its reputation and trust among stakeholders.
The most recent analyst rating on (AU:PME) stock is a Hold with a A$130.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has released its annual report for the year ending June 30, 2025, emphasizing its commitment to integrated reporting. The report outlines the company’s adherence to the International Integrated Reporting Framework, aiming for transparency and long-term value creation. It includes comprehensive information on Pro Medicus’ operations, governance, and financial performance. The company has implemented rigorous processes to ensure the integrity of its reporting, including independent audits and stakeholder engagement. This approach is expected to enhance the company’s industry positioning and stakeholder trust.
The most recent analyst rating on (AU:PME) stock is a Hold with a A$130.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited reported a significant increase in its financial performance for the year ending June 30, 2025. The company achieved a 31.9% rise in revenue from customer contracts, reaching A$212.98 million, and a 39.2% increase in net profit attributable to members, totaling A$115.217 million. This growth reflects the company’s strong market positioning and operational efficiency, with a notable increase in dividends, highlighting its commitment to returning value to shareholders.
The most recent analyst rating on (AU:PME) stock is a Hold with a A$130.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has announced a financing agreement with 4DMedical to support the development and commercialization of 4DMedical’s lung function imaging and analysis software. This strategic move is expected to enhance Pro Medicus’s position in the health imaging industry and potentially expand its market reach, benefiting stakeholders through improved product offerings.
The most recent analyst rating on (AU:PME) stock is a Hold with a A$130.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
4DMedical Limited has secured a $10 million strategic investment from Pro Medicus, a leading medical imaging software company, to accelerate its commercial pipeline and advance its CT:VQ™ product towards regulatory clearance in the U.S. This investment, structured as a hybrid debt and equity loan, provides growth capital without diluting shares if 4DMedical’s share price remains stable, while aligning interests with Pro Medicus if the share price rises. The agreement also allows Pro Medicus to distribute 4DMedical products, potentially enhancing their market reach and operational capabilities.
The most recent analyst rating on (AU:PME) stock is a Hold with a A$130.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.